LJI has a strong research focus in human health and human diseases. We are interested in applicants from any area of immunology and we particularly welcome applicants with research emphasis on autoimmunity, engineering immunity, and sex-based immunological differences.

Applicants should electronically submit a single attachment that includes (1) a cover letter, (2) curriculum vitae, (3) a research statement with research accomplishments and proposed research program (<3 pages), and (4) 3 reference contacts.
jobs.dayforcehcm.com/en-US/lji/CA...

Faculty candidates must hold a PhD, MD, or equivalent degree and must have an outstanding record of scientific ability demonstrated by a strong publication record.

With the Schief lab we’ve shown that individual germline targeting immunogens can effectively prime bnAb-class responses in primates. The bnAb studies this work was based on:
* www.science.org/doi/full/10...., * www.nature.com/articles/s41..., * www.science.org/doi/10.1126/...

Continuity of NIH funding has been central to the exceptional success of these projects.

We are proud that our consortium’s findings over the past 10+ years have substantially advanced HIV vaccine development, and have made many findings—technological, immunological, and in vaccinology—that have accelerated research in many areas of immunology and beyond.

This work was made possible by continuous funding from the NIH over the past 10+ years. These HIV vaccine development studies take extensive coordination between labs.

This project was led by Harry Sutton in the lab in collaboration Schief lab @scripps.edu
A back-to-back paper by the fantastic Batista lab shows similar outcomes in mouse models, with the added advantage of showing success with mRNA vaccines.
www.science.org/doi/10.1126/...

No study had previously reported even a single detectable event of two bnAb lineages targeting distinct epitopes in vaccinated humans or outbred animals.

These findings demonstrate that multi-target GT vaccination is feasible, an important step toward an effective and practical HIV vaccine.

We isolated a total of 13 BG18-class (V3/glycan), 84 PCT64-class (Apex), and 134 10E8-class (MPER) unique clonal lineages from primates that received a triple combination GT immunization regimen. To our knowledge, this is the first report of its kind.

An effective HIV vaccine will likely need to elicit multiple bnAb classes simultaneously. In this study, we systematically tested whether different combinations of three HIV GT immunogens could prime bnAb-class responses. Turns out, the immune system can handle multitasking just fine.

4/ The photo is one of my favorites of David. In his lab, circa 1971, the era of the reverse transcriptase discoveries.

For those interested in a deeper dive:
a.co/d/cOKmZWx

3/ Many of his trainees have gone on to be leaders in their fields for decades, elected to the National Academies, and been heads of universities.

2/ There were those who said he should have easily won two Nobel Prizes. He had a tumultuous tenure as President of Rockefeller University, followed by a highly success tenure as President of Caltech. Perhaps his most enduring legacy is the incredible cadre of scientists who trained in his lab

bsky.app/profile/prof...

“The field has made enormous progress in the last two or three years, and this is a reward for the investments that the federal government has made in these programs,” said Dennis Burton, @scripps.edu .

“Now is not the time to end these efforts,” warned Burton.